The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

ATTO01310 targets IL31, while ATTO-002 hits both IL31 and IL13. The first clinical trial, of ATTO-002, is due to get underway next year. The financing was led by Goldman Sachs Alternatives ...

In a recent example, it was used in a phase 2 trial of AstraZeneca’s anti-IL13 antibody tralokinumab, already on the market as Adtralza, involving patients with idiopathic pulmonary fibrosis (IPF).

Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the IL4 and IL13 pathways and is not an immunosuppressant. The Dupixent development program has shown ...

You are one of 7.5 million annual visitors to OpenSecrets. If you each donated just $1 a year, we'd never worry about funding again.

The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, m ...

You are one of 7.5 million annual visitors to OpenSecrets. If you each donated just $1 a year, we'd never worry about funding again.

9月13日，国家卫生健康委、财政部等部门公布，将慢阻肺患者健康服务纳入国家基本公共卫生服务项目。同日，全球慢阻肺病指数（COPD Index）正式 ...

Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI: Paris Saturday, October 26, 2024, 12:00 Hrs [IST] Positive data from the ...